生物标志物作为阿尔茨海默病临床试验的终点
Yomna Elghanam1, Sujata Purja1, Eun Young Kim1,2,3
1Department of Health, Evidence-Based and Clinical Research Laboratory, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul, Korea.
Journal of Alzheimer's disease : JAD
|April 26, 2024
概括
生物标志物越来越多地被用作阿尔茨海默病 (AD) 临床试验的终点,特别是在后期阶段. 这一趋势反映了它们在诊断阿尔茨海默病和开发新治疗方法方面日益重要.
科学领域:
- 神经科学是一个神经科学.
- 临床试验 临床试验
- 生物标志物研究 生物标志物研究
背景情况:
- 阿尔茨海默氏症 (AD) 是一个重大的全球健康挑战.
- 生物标志物对于诊断AD和开发疾病修饰疗法至关重要.
- 最近的批准强调了生物标志物在AD药物开发中的作用.
研究的目的:
- 分析生物标志物的当前利用和趋势,作为阿尔茨海默病临床试验的终点.
- 了解生物标志物在不同试验阶段的演变作用.
主要方法:
- 对阿尔茨海默病临床试验的回顾性分析.
- 从clinicaltrials.gov收集的数据使用搜索术语"阿尔茨海默病".
- 对于每个试验阶段,分别分析了初级和二级结局.
主要成果:
- 在1,048项试验中,29.87%使用生物标志物作为主要终点和34.73%作为次要终点,主要是在第一和第二阶段.
- 粉样蛋白-PET,粉样蛋白-PET和MRI是主要的初级生物标志物;CSF粉样蛋白-β,血液Aβ和MRI是主要的二级生物标志物.
- 在2期 (初级) 和3期 (二级) 试验中观察到生物标志物采用的统计学上显著增加.
结论:
- 在阿尔茨海默病试验中生物标志物的利用正在稳步增加,特别是在第二和第三阶段.
- 这一趋势凸显了生物标志物在试验设计和阿尔茨海默氏症治疗开发中的公认重要性.
- 这些发现支持生物标志物的持续整合,以推进阿尔茨海默病的研究和治疗.
相关概念视频
01:26Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
01:22Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
81
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
81